Breaking News
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Duration of respiratory disturbances may better predict mortality risk from OSA
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
October 21, 2018 - Gabapentin Beats Pregabalin for Chronic Sciatica
October 21, 2018 - Cosmetic surgeons offering incomplete information for breast augmentation customers
October 21, 2018 - Chronic sleep disruption in early adult life accelerates AD-related tau pathology
October 21, 2018 - Take 10 for Mindfulness – Drugs.com MedNews
October 21, 2018 - Length of breathing disruption in OSA may be better predictor of mortality risk
October 21, 2018 - ApoE4 gene linked with chronic inflammation increases risk for Alzheimer’s disease
October 21, 2018 - Mother-daughter conflict associated with suicide risk in abused adolescent girls
Young-Onset Breast Cancer Survival Unaffected by BRCA Status

Young-Onset Breast Cancer Survival Unaffected by BRCA Status

image_pdfDownload PDFimage_print

Action Points

  • Note that this observational study of young (less than age 40) women with breast cancer demonstrated similar survival after diagnosis regardless of BRCA mutation status.
  • Interestingly, prompt bilateral mastectomy did not confer a survival advantage among the BRCA carriers.

BRCA-positive breast cancer is associated with survival rates similar to those for BRCA-negative cancer in young women after treatment, according to a large, ongoing, prospective study in the U.K.

BRCA carriers with triple-negative breast cancer, however, may have a survival advantage over those without the mutation in the first few years after diagnosis, reported Diana M. Eccles, MD, of the University of Southampton School of Medicine, and colleagues in The Lancet Oncology.

“Women diagnosed with early breast cancer who carry a BRCA mutation are often offered double mastectomies soon after their diagnosis or chemotherapy treatment; however, our findings suggest that this surgery does not have to be immediately undertaken along with the other treatment,” Eccles said in a statement.

“In the longer term, risk-reducing surgery should be discussed as an option for BRCA1 mutation carriers in particular, to minimize their future risk of developing a new breast or ovarian cancer,” she added. “Decisions about timing of additional surgery to reduce future cancer risks should take into account patient prognosis after their first cancer, and their personal preferences.”

While only 5% of breast cancers are diagnosed in women under age 40, a significant proportion of deaths from breast cancer occur in this age group, including a high number who carry a pathogenic BRCA1 or BRCA2 mutation. Second primary breast cancers also are more frequent in high-risk gene carriers.

For the study, called POSH (Prospective Outcomes in Sporadic versus Hereditary), the researchers recruited female patients from 127 hospitals in the U.K. who were ages 18 to 40 when first diagnosed with invasive breast cancer, excluding those with a previous invasive malignancy. Recruitment stopped in 2008, and long-term follow-up is continuing.

All patients received treatment according to local protocols. Nearly 90% underwent chemotherapy. Half had breast-conserving surgery, and half had a mastectomy. The most common chemotherapy regimen was anthracycline, with or without taxanes.

The researchers examined detailed clinical follow-up information, including date and site of disease recurrence, at 6 months and 12 months, and then annually.

The primary outcome was overall survival — defined as the time from first diagnosis to death from any cause — comparing all BRCA1 or BRCA2 mutation carriers (BRCA-positive) with non-carriers (BRCA-negative). The secondary outcome was distant disease-free survival, defined as time from initial diagnosis to first distant disease.

Of 2,733 patients in the POSH analysis, 338 (12%) carried either a BRCA1 or BRCA2 mutation. Of the total sample, 558 women (20%) had triple-negative breast cancer. BRCA mutations were identified in 136 (24%) of patients with triple-negative breast cancer, and 123 of these women (90%) had a BRCA1 mutation.

The median follow-up was 8.2 years. In that period, 678 women died — 651 due to breast cancer.

The survival rates for both BRCA carriers and non-carriers were similar: after 2 years, the survival rates were 97% for carriers and 96.6% for non-carriers. After 5 years, the rates were 83.8% and 85%, and after 10 years, 73.4% versus 70.1%. Distant disease-free survival rates also were similar in both groups.

These results did not vary between unadjusted or adjusted analyses, including adjustments for ethnicity and body mass index.

Immediate bilateral mastectomy also was not associated with improved survival.

A subgroup analysis of 558 women with triple-negative breast cancer suggested that BRCA carriers initially may have better overall survival than women not carrying the mutation — 95% versus 91% at 2 years — but survival was similar at 5 or 10 years, for unclear reasons. This early survival advantage also has been seen in ovarian cancer patients who have the BRCA mutation, the authors noted.

Asked for her perspective, Virginia Kaklamani, MD, DSc, of the University of Texas Health Science Center at San Antonio, who was not involved in the study, said: “This is the largest prospective study looking at outcomes in BRCA-related breast cancer. Prior studies have shown some conflicting results regarding the breast cancer-related prognosis, but most have pointed to the fact that breast cancer outcomes are similar between BRCA carriers and non-carriers. This study confirms these findings.”

In an editorial accompanying the study, Peter Fasching, MD, of the Friedrich Alexander University Erlangen-Nuremberg in Germany, observed that while 338 patients in the POSH cohort had a BRCA1 or BRCA2 mutation, only 54% of the mutation carriers — 182 women — had been identified through routine healthcare.

“In most national and international guidelines, testing criteria include patients with breast cancer ages less than 35 or 40,” he wrote. “The fact that in the POSH study there were 155 young women diagnosed with breast cancer who did not know their mutation status raises the question of whether and when testing criteria for certain groups of patients can be allowed for lower mutation probabilities.”

Limitations of the study, the authors noted, included the fact that since it was restricted to women 40 or younger, the observations in young patients might not translate to women who were older when diagnosed. In addition, because triple-negative breast cancer was not well understood when the study was designed, it was therefore not powered for this as a primary outcome. Furthermore, breast cancer treatment recommendations in the U.K. also changed over the course of recruitment, which may have affected the survival rates.

The study was funded by Cancer Research UK, the UK National Cancer Research Network, the Wessex Cancer Trust, Breast Cancer Now, and the PPP Healthcare Medical Trust Grant.

The authors reported financial relationships with Roche, GSK, Pfizer, AstraZeneca, and Pierre Fabre.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-01-13T10:00:00-0500

Tagged with:

About author

Related Articles